Nuwellis announces first commercial sale of QUELIMMUNE therapy for pediatric AKI/sepsis

Nuwellis, Inc.

First commercial sale of QUELIMMUNE to Cincinnati Children's Hospital for pediatric AKI/sepsis patients.
QUELIMMUNE (Selective Cytopheretic Device) developed by SeaStar Medical; early data show 77% survival rate.
Sale under exclusive US distribution agreement with SeaStar Medical (ICU); FDA Humanitarian Device Exemption.
Dr. Stuart Goldstein, principal investigator, will integrate QUELIMMUNE as standard of care at Cincinnati Children's.
CEO Nestor Jaramillo: milestone advances Nuwellis' pediatric business development strategy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.